AbbVie, Sosei Heptares enter $409M deal to discover, develop immunology drugs
The Japanese drugmaker had entered a neurology-focused partnership with Allergan in April 2016. AbbVie acquired Allergan last year, closing the deal in May.
Drugmakers’ financial fortunes during Covid-19 may hinge on their product mix
Analyst reports over the past few weeks have looked into what effects the Covid-19 pandemic could have on drugmakers' sales, examining multiple factors. But virtual launches and telemedicine could mitigate some market challenges.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The top biopharma companies targeting NASH
These are four companies that currently have drugs in Phase III development for nonalcoholic steatohepatitis or have them under Food and Drug Administration review.
Allergan to divest two drugs to satisfy regulators in $63B acquisition by AbbVie
One of the buyers, AstraZeneca, said separately that it would divest several hypertension drugs as it shifts the focus of its pipeline to newer medicines.
Biopharma analyst: Excitement/Skepticism building over new Alzheimer’s drug
Chinese regulators gave conditional approval to a new drug with a different mechanism of action giving new hope to Alzheimer's Disease patients and while the excitement is warranted so is skepticism.
presented by
Geopolitical, economic concerns unlikely to stem pharma, life science industry capital deployment, report finds
Deal value for the third quarter fell sharply from what it was in the first and second quarter, but that was due to the absence of the large acquisitions that took place earlier this year rather than an overall downward trend.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Why is biosimilar adoption slow in the U.S., and can something be done to boost uptake?
Although the pathway for biosimilars has existed nearly a decade, adoption has lagged behind Europe. Interviewed experts pointed to physician education and the market's immaturity as significant factors.
Senators urge greater FTC scrutiny over large biopharma mergers
Nine senators sent a letter to FTC Chairman Joseph Simons urging greater scrutiny over like the one between BMS and Celgene, expressing concern over antitrust issues, innovation and drug pricing.
Editas, Allergan open first trial of in vivo CRISPR therapy
One of the four sites of the trial, in a rare form of inherited blindness, is currently listed as open for enrollment, and the companies plan to dose the first patient soon.
Allergan recalls Biocell breast implants, warns physicians not to use them
The company initiated the voluntary recall of textured Biocell breast implants and tissue expanders after it received a warning from the FDA that they were linked to some cases of a type of T-cell lymphoma.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
AbbVie to buy Botox maker Allergan for $63B
The companies said the acquisition would diversify AbbVie's portfolio. However, Allergan also faces headwinds from generic competition. A bid to stop a challenge to the patents on its second top-selling drug failed earlier this year.
Supreme Court rejects Allergan, Saint Regis Mohawk appeal in patent case
The rejection brings to an end an effort by the drugmaker and Native American tribe to invoke sovereign immunity to protect patents covering the dry-eye drug Restasis.
Clinical trials of Allergan’s antidepressant rapastinel fail
An analyst said the news could negatively affect shares of a successor to the company that developed rapastinel - which Allergan bought in 2015 - given that its drugs belong to the same class.
Editas Medicine CEO steps down as company moves into product development stage
Shares of gene-editing companies were down Tuesday morning following the news, but analysts sought to reassure investors about Editas.
Allergan, Saint Regis Mohawk Tribe ask SCOTUS to hear Restasis patent case
A federal court last year put the kibosh on a deal whereby Allergan transferred to the tribe the Restasis patents, which the tribe then licensed back to Allergan, asserting tribal sovereign immunity to have generic companies' challenge to the patents dismissed.